FDA approves first targeted therapy for Alexander disease
The FDA approved Zanvastro, the first treatment that directly targets Alexander disease, an extremely rare and often fatal neurological condition. The drug came from more than 30 years of research at the University of Wisconsin-Madison, and trials showed stabilized motor function with some patients improving.
Zanvastro is the first approved medicine that acts on Alexander disease itself rather than only relieving symptoms. The condition affects fewer than one person per million and can impair movement, cognition, breathing, and heart regulation; onset and severity vary widely from infancy to adulthood.
Its development grew from three decades of work at the University of Wisconsin-Madison, including Albee Messing’s laboratory and a collaboration with Ionis Pharmaceuticals. In the late 1990s, Messing and Michael Brenner linked the disease to genetic changes involving GFAP, a protein found in brain-supporting astrocytes. Trials showed motor function generally stabilized, with some participants gaining movement.
For families facing Alexander disease, an approved therapy that targets the disease process may change the emotional and practical landscape, offering hope where only symptom management existed. Because the disorder is ultra-rare, its broader societal footprint is likely small, but the approval could encourage investment in treatments for other rare neurological conditions. Access, cost, and long-term benefit remain uncertain and may shape how widely the impact is felt.